Access to Drugs for Treatment of Noncommunicable Diseases

PLoS Medicine

Volumn 10, Issue 7, 2013, Pages

  Bollyky, Thomas J ^a  

^a and Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; IMATINIB;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DEVELOPING COUNTRY; DRUG INDUSTRY; FINANCIAL MANAGEMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LICENCE; NON COMMUNICABLE DISEASE; PATENT; PUBLIC HEALTH;

EID: 84881257573     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001485     Document Type: Article

References (30)

1. Nwaka S, Ramirez B, Brun R, Maes L, Douglas F, et al. (2009) advancing drug innovation for neglected diseases-criteria for lead progression. PLoS Negl Trop Dis 3: e440 doi:10.1371/journal.pntd.0000440.
2. Fink C, Maskus KE (2005) Intellectual property and development: lessons from recent economic research. Washington (D.C.); New York: World Bank; Oxford University Press.
3. Sachs JD, (2001) A new global commitment to disease control in Africa. Nat Med 7: 521-523 doi:10.1038/87830.
4. Hoen E, Berger J, Calmy A, Moon S, (2011) Driving a decade of change: HIV/AIDS, patents and access to medicines for all. J Int AIDS Soc 14: 15.
5. World Trade Organization (1995) Agreement on trade-related aspects of intellectual property rights, article 31. Available: http://www.wto.org/english/tratop_e/trips_e/t_agm3_e.htm#1. Accessed 12 March 2013.
6. Beall R, Kuhn R, (2012) Trends in Compulsory Licensing of Pharmaceuticals Since the Doha Declaration: A Database Analysis. PLoS Med 9: e1001154 doi:10.1371/journal.pmed.1001154.
7. University of Washington. Institute for Health Metrics and Evaluation (2012) Financing global health 2012 the end of the golden age? Seattle (Washington): Institute for Health Metrics and Evaluation, University of Washington. Available: http://www.healthmetricsandevaluation.org/sites/default/files/policy_report/2011/FGH_2012_full_report_medium_resolution_IHME.pdf. Accessed 8 March 2013.
8. Moran M, Guzman J, Henderson K, Liyanage R, Wu L, et al. (2012) Neglected disease research and development: a five year review. Policy Cures. Available: http://www.policycures.org/downloads/GF2012_Report.pdf. Accessed 12 March 2013.
9. GAVI Alliance (2013) What we do. What we do. Available: http://www.gavialliance.org/about/mission/what/. Accessed 12 March 2013.
10. The Global Fund to Fight AIDS, Tuberculosis and Malaria (2013) Who we are. Available: http://www.theglobalfund.org/en/about/whoweare/. Accessed 12 March 2013.
11. Committee on the Outcome and Impact Evaluation of Global HIV/AIDS Programs Implemented Under the Lantos-Hyde Act of 2008; Board on Global Health; Board on Children, Youth, and Families; Institute of Medicine (2013) Evaluation of PEPFAR. Washington (D.C.): The National Academies Press. 850 p.
12. Bollyky T (2012) Better, cheaper, faster: strategies for sustainable treatment access for the world's poorest. Available: http://papers.ssrn.com/abstract=1999061. Accessed 8 March 2013.
13. Global Task Force on Expanded Access to Cancer Care and Control in Developing Countries (2011). Boston: Harvard Global Equity Initiative. Available: http://ghsm.hms.harvard.edu/uploads/pdf/ccd_report_111027.pdf. Accessed 12 March 2013.
14. McArthur JW (2013) Own the goals. Foreign Affairs. Available: http://www.foreignaffairs.com/articles/138821/john-w-mcarthur/own-the-goals. Accessed 12 March 2013.
15. Novartis AG V. Union of India and Others (2013) Available: http://judis.nic.in/supremecourt/imgs1.aspx?filename=40212. Accessed 1 April 2013.
16. Ghosh A (2013) Govt moves to make three key cancer drugs cheaper. Indian Express. Available: http://www.indianexpress.com/news/govt-moves-to-make-three-key-cancer-drugs-cheaper/1058247/. Accessed 12 January 2013.
17. IHS (2012) Indonesia issues compulsory licences against seven HIV, hepatitis drugs. Country & Industry Forecasting: IHS Global Insight. Available: http://www.ihs.com/products/global-insight/industry-economic-report.aspx?id=1065972339. Accessed 12 March 2013.
18. Lyn TE (2012) China changes patent law in fight for cheaper drugs. Reuters. Available: http://www.reuters.com/article/2012/06/08/us-china-medicines-patents-idUSBRE8570TY20120608. Accessed 12 March 2013.
19. Singh K (2012) More nations adopting Indian intellectual property regulations for drug manufacturing. The Economic Times. Available: http://articles.economictimes.indiatimes.com/2012-06-22/news/32368898_1_compulsory-licence-intellectual-property-shamnad-basheer. Accessed 12 March 2013.
20. Alwan A, World Health Organization (2011) Global status report on noncommunicable diseases 2010. Geneva, Switzerland: World Health Organization. Available: http://www.who.int/nmh/publications/ncd_report_full_en.pdf. Accessed 12 March 2013.
21. Bloom DE, Jané-Llopis E, Cafiero E.T., Abrahams-Gessel S., Bloom L.R., et al. (2011) The Global Economic Burden of Non-communicable Diseases. Geneva: World Economic Forum. Available: http://www3.weforum.org/docs/WEF_Harvard_HE_GlobalEconomicBurdenNonCommunicableDiseases_2011.pdf. Accessed 12 March 2013.
22. Cameron A, Roubos I, Ewen M, Mantel-Teeuwisse AK, Leufkens HG, et al. (2011) Differences in the availability of medicines for chronic and acute conditions in the public and private sectors of developing countries. Bull World Health Organ 89: 412-421.
23. PriceWaterhouseCoopers LLC (2012) From vision to decision: Pharma 2020. Available: http://download.pwc.com/ie/pubs/2012_pharma_2020.pdf.
24. Glassman A, Duran D, Sumner A (2011) Global health and the new bottom billion: what do shifts in global poverty and the global disease burden mean for GAVI and the global fund? Working Paper. Washington (D.C.): Center for Global Development. Available: http://www.cgdev.org/files/1425581_file_Glassman_Duran_Sumner_MIC_global_health_FINAL.pdf.
25. IMS Institute for Healthcare Informatics (2012) The global use of medicines: outlook through 2016. Parsippany (New Jersey): IMS Institute for Healthcare Informatics. Available: http://www.imshealth.com/deployedfiles/ims/Global/Content/Insights/IMS%20Institute%20for%20Healthcare%20Informatics/Global%20Use%20of%20Meds%202011/Medicines_Outlook_Through_2016_Report.pdf. Accessed 12 March 2013.
26. Palmer D (2013) U.S. urged to take tougher line on Indian trade practices. Reuters. Available: http://www.reuters.com/article/2013/05/14/us-usa-india-trade-idUSBRE94D13U20130514. Accessed 17 May 2013.
27. World Trade Organization (2010) Members ask: Is the "Par.6" system on intellectual property and health working? WTO 2010 News Items. Available: http://www.wto.org/english/news_e/news10_e/trip_02mar10_e.htm. Accessed 18 May 2013.
28. Mimura C (2010) Chapter 9: nuanced management of IP rights: shaping industry-university relationships to promote social impact. Working within the boundaries of intellectual property: innovation policy for the knowledge society. New York: Oxford University Press. pp. 269-295.
29. Hogerzeil HV, Liberman J, Wirtz VJ, Kishore SP, Selvaraj S, et al. (2013) Promotion of access to essential medicines for non-communicable diseases: practical implications of the UN political declaration. Lancet 381: 680-689.
30. Yadav P (2010) Differential pricing for pharmaceuticals: review of current knowledge, new findings and ideas for action. White Paper. Available: http://www.accesstomedicineindex.org/sites/www.accesstomedicineindex.org/files/yadav_differential_pricing_for_pharmaceuticals.pdf. Accessed 12 March 2013.